Oral Rimegepant in Adults With Migraine and Cardiovascular Risk Factors
Neurology Minute · Anna Rehbein
April 24, 20213m 40s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. Susan Hutchinson discusses her abstract, "Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study".
You can view her abstract and others here: https://index.mirasmart.com/AAN2021/